-
Everest Medicines’ EVER206 Shows Positive Phase I Results in China
•
China-based Everest Medicines (HKG: 1952) has announced top-line results from a Phase I study in China, demonstrating that EVER206 (also known as SPR206), a novel intravenous polymyxin derivative, is well-tolerated with no evidence of acute kidney injury or new safety signals. The study supports Everest’s plans to initiate next-phase clinical…
-
Bliss Bio Raises RMB 100 Million in Series B+ Financing for Oncology Pipeline
•
Hangzhou-based oncology-focused clinical-stage biotech Bliss Bio has reportedly raised over RMB 100 million (USD 14.7 million) in a Series B+ financing round. The round was led by In Capital, with contributions from Oriental Fortune Capital and Sherpa Healthcare Partners. The proceeds will be used to advance clinical studies for BB-1701,…
-
Junshi Biosciences’ Neotorch Study Achieves Superiority in Lung Cancer Trial
•
Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced that its randomized, double-blind, placebo-controlled, multi-center Phase III Neotorch study has completed the pre-set interim analysis. The study assessed the efficacy and safety of its programmed death-1 (PD-1) inhibitor Tuoyi (toripalimab) combined with chemotherapy as a perioperative treatment for patients…
-
Hengrui’s EZH2 Inhibitor SHR2554 Nears Breakthrough Therapy Designation
•
China-based Jiangsu Hengrui Pharmamceuticals (SHA: 600276) has announced that its enhancer for the zeste homolog 2 (EZH2) inhibitor, SHR2554, is set to obtain breakthrough therapy designation (BTD) status from the Center for Drug Evaluation (CDE) in China. The designation is for use in relapsed/refractory (r/r) peripheral T-cell lymphoma, marking a…
-
Henlius Terminates TROP2 Antibody Licensing Deal with Chiome Bioscience
•
Shanghai Henlius Pharmaceutical Co., Ltd (HKG: 2696) has announced the termination of a licensing deal with Japan-based Chiome Bioscience Inc. effective January 17, 2023. The agreement, originally signed in January 2021, granted Henlius exclusive development, manufacturing, and commercialization rights to Chiome’s anti-trophoblast cell surface antigen 2 (TROP2) antibody. The decision…
-
Structure Therapeutics Files for IPO on NASDAQ to Raise $119M
•
Structure Therapeutics Inc. (Nasdaq: GPCR), a Sino-US firm formerly known as ShouTi Inc., has filed for an initial public offering (IPO) on the NASDAQ stock exchange. The company aims to raise USD 119 million gross through the issuance of American Depositary Shares (ADS), though the final figure may differ. Structure…
-
Hansoh’s HS-10517 Greenlit for COVID-19 Clinical Study by NMPA
•
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced receiving approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its HS-10517, a Category 1 anti-COVID-19 drug co-developed by the Global Health Drug Discovery Institute (GHDDI). The study will focus on mild to moderate COVID-19…
-
Cowell Health Partners with Gilead Sciences to Enhance Drug Accessibility
•
Cowell Health has announced a partnership with US-based Gilead Sciences, Inc., (NASDAQ: GILD) aimed at leveraging Cowell’s smart pharmacy, integrated health management services, patient education, intelligent supply chain, and Internet “medicine + drug” platform, alongside Gilead’s expertise in disease prevention and treatment. The collaboration will focus on channel construction, operations,…
-
IASO Bio Raises RMB 500 Million in Series C1 Funding for Cell Therapy Pipeline
•
China-based IASO Biotherapeutics has announced the completion of a nearly RMB 500 million (USD 73.7 million) Series C1 funding round. The round was led by Shanghai Guoxin Investment & Development, Efung Capital, Shanghai Waigaoqiao Free Trade Zone Group, Nanjing Jiangbei New Area State-owned Asset Management, Housen Care Brothers, and Hongcheng…
-
Junshi Biosciences’ COVID-19 Drug JT001 (VV116) Accepted for NMPA Review
•
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that its oral nucleoside analog drug JT001 (VV116) for treating COVID-19 has been accepted for review by the National Medical Products Administration (NMPA). This marks a significant step forward in the development and potential market approval of the drug in China.…
-
Bristol-Myers Squibb’s Opdivo Gains New Indication for NSCLC Neoadjuvant Therapy in China
•
US-based pharmaceutical giant Bristol-Myers Squibb (BMS, NYSE: BMY) has secured another indication approval in China for its PD-1 inhibitor Opdivo (nivolumab). The immunotherapy is now approved for use in combination with chemotherapy as neoadjuvant therapy for adult patients with resectable non-small cell lung cancer (NSCLC), regardless of PD-L1 expression levels.…
-
Daiichi Sankyo’s Mirogabalin Nears China Market Entry with CDE Review
•
Japan-based Daiichi Sankyo Inc. (TYO: 4568) has announced that China’s Center for Drug Evaluation (CDE) has accepted its market approval filing for mirogabalin besylate, a novel chronic pain treatment. The drug is specifically targeted at diabetic peripheral neuropathic pain (DPNP), a condition that affects a significant number of patients with…
-
Bio-Thera’s Biosimilar BAT1806 Passes NMPA Review, Targets Roche’s Actemra
•
China-based Bio-Thera Solutions Ltd (SHA: 688177) has announced that its biosimilar drug BAT1806, modeled after Roche Holding AG’s (OTCMKTS: RHHBY) blockbuster Actemra/RoActemra (tocilizumab), has successfully passed review by the National Medical Products Administration (NMPA). This milestone positions Bio-Thera to enter a market dominated by Roche’s originator drug, which has been…
-
Abbisko’s ABSK021 Gains NMPA Approval for Phase II Study in cGVHD
•
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced receiving approval from the National Medical Products Administration (NMPA) to conduct a Phase II clinical study for its Category 1 drug ABSK021 (pimicotinib) in chronic graft versus host disease (cGVHD). This marks a significant step forward in the development of…
-
AffaMed Secures China Rights to Eli Lilly’s Migraine Drug Galcanezumab
•
China-based AffaMed Therapeutics has announced an agreement with Eli Lilly and Company to obtain sole commercialization rights for galcanezumab in mainland China. The monoclonal antibody, developed by Eli Lilly, selectively binds to the calcitonin gene-related peptide (CGRP) and was approved by the FDA in September 2018 for the preventive treatment…
-
Suzhou Powersite Electric Secures Series B Funding for X-ray Imaging Expansion
•
China-based X-ray imaging core component supplier Suzhou Powersite Electric Co., Ltd has reportedly raised hundreds of millions of renminbi in a Series B financing round. The round was led by Yuanbio Venture Capital, with contributions from Suzhou High-Tech Venture Capital, Medpark, Northern Light Venture Capital, Cross Currents Capital, and SND…
-
Beijing Interbio Secures Pre-Series A Funding for SPR Technology Expansion
•
Beijing Interbio Biology & Technology Co., Ltd, a China-based company specializing in surface plasmon resonance (SPR) technology and other life sciences testing instruments, has reportedly raised an undisclosed amount in a Pre-Series A financing round led by Jintan Capital. The proceeds will be used to support commercial equipment installation, mass…
-
CStone’s RET Inhibitor Gavreto Approved in Taiwan for Lung and Thyroid Cancers
•
CStone Pharmaceuticals (HKG: 2616) has announced receiving marketing approval in Taiwan for its RET inhibitor Gavreto (pralsetinib), a drug in-licensed from US-based biotech Blueprint Medicines in June 2018. The approval covers the treatment of adults with locally advanced or metastatic RET fusion-positive non-small cell lung cancer (NSCLC), advanced or metastatic…
-
Ascletis Partners with Simcere for Ritonavir Supply in COVID-19 Drug Development
•
China-based Ascletis Pharma Inc. (HKG: 1672) has announced that its wholly-owned subsidiary Ascletis Pharmaceuticals Co., Ltd has entered into a supply agreement for ritonavir tablets with Hainan Simcere Pharmaceutical Co., Ltd, a subsidiary of Simcere Pharmaceutical Group Limited (HKG: 2096). This partnership aims to support the development and supply chain…
-
Simcere’s COVID-19 Drug SIM0417 Accepted for Special Review by NMPA
•
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced that the National Medical Products Administration (NMPA) has accepted a New Drug Application (NDA) for SIM0417 into its special review channel. The oral COVID-19 drug candidate is co-developed with the Chinese Academy of Science’s Shanghai Institute of Materia Medica (SIMM) and the…
